Paratek Pharmaceuticals Inc (was acquised by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings") on 21/09/2023) (PRTK)
Paratek Pharmaceuticals to Present New Data onNUZYRA® (omadacycline) at ESCMID Global 2026
Paratek Pharmaceuticals to Present New Data onNUZYRA® (omadacycline) at ESCMID Global 2026
📉 **NEGATIVE** • Medium confidence analysis (67%) • Mild negative signal • Limited downside risk **Sentiment:** Negative (5%) **Content type:** General